Exicure, Inc. – NASDAQ:XCUR
Exicure stock price today
Exicure stock price monthly change
Exicure stock price quarterly change
Exicure stock price yearly change
Exicure key metrics
Market Cap | 55.51M |
Enterprise value | 3.27M |
P/E | -1.9 |
EV/Sales | 0.11 |
EV/EBITDA | 8.60 |
Price/Sales | 0.17 |
Price/Book | 0.34 |
PEG ratio | -0.01 |
EPS | -1.55 |
Revenue | N/A |
EBITDA | -9.36M |
Income | -13.33M |
Revenue Q/Q | N/A |
Revenue Y/Y | -96.13% |
Profit margin | -8.96% |
Oper. margin | -18.06% |
Gross margin | 6.99% |
EBIT margin | -18.06% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeExicure stock price history
Exicure stock forecast
Exicure financial statements
| Jun 2023 | 0 | -5.76M | |
|---|---|---|---|
| Sep 2023 | 0 | -5.25M | |
| Dec 2023 | 516K | -1.48M | -288.18% |
| Mar 2024 | 500K | -829K | -165.8% |
| 2025 | 63.15M | -125.01M | -197.95% |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 17555000 | 7.85M | 44.72% |
|---|---|---|---|
| Sep 2023 | 12950000 | 8.45M | 65.27% |
| Dec 2023 | 11580000 | 8.54M | 73.83% |
| Mar 2024 | 10711000 | 8.50M | 79.4% |
| Jun 2023 | -4.81M | -1.89M | -919K |
|---|---|---|---|
| Sep 2023 | -1.41M | 0 | -1K |
| Dec 2023 | -816K | 711K | -1K |
| Mar 2024 | -450K | 0 | 0 |
Exicure alternative data
| Aug 2023 | 9 |
|---|---|
| Sep 2023 | 7 |
| Oct 2023 | 7 |
| Nov 2023 | 7 |
| Dec 2023 | 7 |
| Jan 2024 | 7 |
| Feb 2024 | 7 |
| Apr 2024 | 7 |
| May 2024 | 7 |
| Jun 2024 | 13 |
| Jul 2024 | 5 |
Exicure other data
| Period | Buy | Sel |
|---|---|---|
| Sep 2024 | 237223 | 0 |
| Patent |
|---|
Application Filling date: 15 Apr 2021 Issue date: 3 Mar 2022 |
Application Filling date: 20 Jun 2019 Issue date: 2 Sep 2021 |
Application SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOSTIMULATORY AGENTS FOR PROPHYLACTIC AND THERAPEUTIC USE Filling date: 8 Oct 2020 Issue date: 8 Apr 2021 |
Application Filling date: 3 Sep 2020 Issue date: 25 Feb 2021 |
Grant Utility: Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use Filling date: 25 Jul 2014 Issue date: 19 Jan 2021 |
Application Filling date: 28 Feb 2019 Issue date: 7 Jan 2021 |
Grant Utility: Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use Filling date: 15 May 2018 Issue date: 17 Nov 2020 |
Application Filling date: 16 Jul 2020 Issue date: 29 Oct 2020 |
Application Filling date: 26 May 2020 Issue date: 29 Oct 2020 |
Grant Filling date: 8 Jan 2019 Issue date: 6 Oct 2020 |
-
What's the price of Exicure stock today?
One share of Exicure stock can currently be purchased for approximately $6.46.
-
When is Exicure's next earnings date?
Unfortunately, Exicure's (XCUR) next earnings date is currently unknown.
-
Does Exicure pay dividends?
No, Exicure does not pay dividends.
-
How much money does Exicure make?
Exicure has a market capitalization of 55.51M.
-
What is Exicure's stock symbol?
Exicure, Inc. is traded on the NASDAQ under the ticker symbol "XCUR".
-
What is Exicure's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Exicure?
Shares of Exicure can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Exicure's key executives?
Exicure's management team includes the following people:
- Dr. David A. Giljohann Chief Executive Officer, Corporation Sec. & Director(age: 44, pay: $836,320)
- Dr. Matthias G. Schroff Ph.D. Chief Operating Officer(age: 57, pay: $525,250)
- Dr. Douglas E. Feltner Chief Medical Officer(age: 65, pay: $423,300)
-
How many employees does Exicure have?
As Jul 2024, Exicure employs 5 workers, which is 62% less then previous month and 29% less then previous quarter.
-
When Exicure went public?
Exicure, Inc. is publicly traded company for more then 7 years since IPO on 22 May 2018.
-
What is Exicure's official website?
The official website for Exicure is exicuretx.com.
-
Where are Exicure's headquarters?
Exicure is headquartered at 2430 North Halsted Street, Chicago, IL.
-
How can i contact Exicure?
Exicure's mailing address is 2430 North Halsted Street, Chicago, IL and company can be reached via phone at +84 76731700.
Exicure company profile:
Exicure, Inc.
exicuretx.comNASDAQ
5
Biotechnology
Healthcare
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Chicago, IL 60614
CIK: 0001698530
ISIN: US30205M2008
CUSIP: 30205M101
